Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APH-1501 in Opioid Addiction
NCT03813095Phase 2Not yet recruiting
- Sponsor
- Aphios
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
01
Overview
Phase 2, randomised, double-blind trial of LPT-CBD in opioid use disorder (OUD) (4 arms), sponsored by Aphios. Primary endpoints: Incidence of Treatment Emergent Adverse Effects and Pharmacokinetics of APH-1501 at 480 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
LPT-CBD
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03813095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813095.